Vera Therapeutics Completes Enrollment For Primary Endpoint In Pivotal Phase 3 ORIGIN 3 Trial Of Atacicept In IgAN
Portfolio Pulse from Benzinga Newsdesk
Vera Therapeutics has completed enrollment for the primary endpoint in its Phase 3 ORIGIN 3 trial of atacicept for IgAN, with results expected in Q2 2025. The company will also present data from a Phase 2b trial in Q4 2024.
September 12, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vera Therapeutics has completed enrollment for its Phase 3 ORIGIN 3 trial of atacicept in IgAN, with results expected in Q2 2025. This milestone supports future regulatory approval efforts.
The completion of enrollment in a pivotal Phase 3 trial is a significant milestone for Vera Therapeutics, indicating progress towards potential regulatory approval. The announcement of topline results in Q2 2025 could be a catalyst for the stock, as positive results may lead to regulatory submissions and eventual commercialization.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100